Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) represented a move of 0 percent or $0.26 per share and closed its previous day trading session at $8.11. 0 Shares were traded in the last trading session with an Average Volume of 195.17 Million Shares. The stock currently has a Market Capitalization of 197.32 Million.
The stock traded between $ 4.57 and $12.00 over 1-Year time period showing its price to sales ratio of 36.54. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-8.73 and 200-Day Simple Moving Average of $-12.58. Its Price to Free Cash Flow is 0 and Price to Book of 2.8.
Analyst’s recommended the stock as 2.2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) reported its Actual EPS of $-0.54/share. The analysts offering Earnings Estimates for the company were believing that Aeglea BioTherapeutics, Inc. could bring EPS of $-0.45/share. The difference between Actual EPS and Estimated EPS was -0.09 Percent. Thus showing an Earnings Surprise of -20 Percent.
Alimera Sciences, Inc. (NASDAQ:ALIM)
In the last trading session, Alimera Sciences, Inc. (NASDAQ:ALIM) added its value by 0% closing at the price of $1.01. The stock currently has market capitalization of 70.74 Million, with average volume of 96 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Alimera Sciences, Inc. (NASDAQ:ALIM) is showing beta of 1.62. This particular value of beta suggests that Alimera Sciences, Inc. (NASDAQ:ALIM) has historically moved 162% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Alimera Sciences, Inc. (NASDAQ:ALIM) is at $0.22.
The stock currently has RSI of 49.56. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Alimera Sciences, Inc. (NASDAQ:ALIM) topped its 52-week high price of $1.38 on 12/26/17 and 52-Week Low Price of $0.74 on 05/18/18. The Stock currently has P/E (price to earnings ttm) of 4.53 and Weekly volatility of 4.88% and monthly volatility of 5.97% respectively.